ASLAN Pharmaceuticals (NASDAQ:ASLN) reported quarterly losses of $(0.16) per share. This is a 6.67 percent decrease over losses of $(0.15) per share from the same period last year.
Citigroup Maintains Buy on Microsoft, Lowers Price Target to $282
Citigroup analyst Tyler Radke maintains Microsoft (NASDAQ:MSFT) with a Buy and lowers the price target from $300 to $282.
